Conditions: Metastatic Breast Cancer
Keywords: HER2-positive breast cancer HER2 MBC Trastuzumab emtansine
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 110
Healthy volunteers: no

Brief summary:
Study of trastuzumab emtansine (T-DM1) administered to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.

Detailed description:

Arms:
arm 1: Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.

Interventions: intervention 1: Trastuzumab emtansine [Kadcyla]
Intervention descriptions: intervention 1: Intravenous repeating dose

Protocol document: